Form 8-K TherapeuticsMD, Inc. For: Mar 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Noble Financial Lifts PT on TherapeuticsMD (TXMD) to $15; Sees Reduced TX 12-001HR Risk
March 11, 2015 11:47 AM EDTNoble Financial affirms TherapeuticsMD, Inc. (AMEX: TXMD) at Buy and nudges its price target from $14 up to $15 following Q4 results and update issued after markets closed Tuesday.
Analyst Nathan Cali noted that the bump higher in TXMD's price target stems from an increased cash balance, lowering the cost of capital by 5 points to 15 percent, and increasing risk-adjusted rNPV for TX 12-001HR, bioidentical estradiol/progesterone.
Cali also noted the following key points from the quarter and recent updates:
March 10th, 2015 reported relatively inline full year 2015 financial... More